274 related articles for article (PubMed ID: 20805362)
1. Transformation by Tribbles homolog 2 (Trib2) requires both the Trib2 kinase domain and COP1 binding.
Keeshan K; Bailis W; Dedhia PH; Vega ME; Shestova O; Xu L; Toscano K; Uljon SN; Blacklow SC; Pear WS
Blood; 2010 Dec; 116(23):4948-57. PubMed ID: 20805362
[TBL] [Abstract][Full Text] [Related]
2. Molecular Mechanism of CCAAT-Enhancer Binding Protein Recruitment by the TRIB1 Pseudokinase.
Murphy JM; Nakatani Y; Jamieson SA; Dai W; Lucet IS; Mace PD
Structure; 2015 Nov; 23(11):2111-21. PubMed ID: 26455797
[TBL] [Abstract][Full Text] [Related]
3. Tribbles homolog 2 inactivates C/EBPalpha and causes acute myelogenous leukemia.
Keeshan K; He Y; Wouters BJ; Shestova O; Xu L; Sai H; Rodriguez CG; Maillard I; Tobias JW; Valk P; Carroll M; Aster JC; Delwel R; Pear WS
Cancer Cell; 2006 Nov; 10(5):401-11. PubMed ID: 17097562
[TBL] [Abstract][Full Text] [Related]
4. COP1 targets C/EBPα for degradation and induces acute myeloid leukemia via Trib1.
Yoshida A; Kato JY; Nakamae I; Yoneda-Kato N
Blood; 2013 Sep; 122(10):1750-60. PubMed ID: 23884858
[TBL] [Abstract][Full Text] [Related]
5. Regulation of Trib2 by an E2F1-C/EBPα feedback loop in AML cell proliferation.
Rishi L; Hannon M; Salomè M; Hasemann M; Frank AK; Campos J; Timoney J; O'Connor C; Cahill MR; Porse B; Keeshan K
Blood; 2014 Apr; 123(15):2389-400. PubMed ID: 24516045
[TBL] [Abstract][Full Text] [Related]
6. Differential ability of Tribbles family members to promote degradation of C/EBPalpha and induce acute myelogenous leukemia.
Dedhia PH; Keeshan K; Uljon S; Xu L; Vega ME; Shestova O; Zaks-Zilberman M; Romany C; Blacklow SC; Pear WS
Blood; 2010 Aug; 116(8):1321-8. PubMed ID: 20410507
[TBL] [Abstract][Full Text] [Related]
7. Nanobodies identify an activated state of the TRIB2 pseudokinase.
Jamieson SA; Pudjihartono M; Horne CR; Viloria JS; Dunlop JL; McMillan HD; Day RC; Keeshan K; Murphy JM; Mace PD
Structure; 2022 Nov; 30(11):1518-1529.e5. PubMed ID: 36108635
[TBL] [Abstract][Full Text] [Related]
8. STK40 Is a Pseudokinase that Binds the E3 Ubiquitin Ligase COP1.
Durzynska I; Xu X; Adelmant G; Ficarro SB; Marto JA; Sliz P; Uljon S; Blacklow SC
Structure; 2017 Feb; 25(2):287-294. PubMed ID: 28089446
[TBL] [Abstract][Full Text] [Related]
9. TRIB2 acts downstream of Wnt/TCF in liver cancer cells to regulate YAP and C/EBPα function.
Wang J; Park JS; Wei Y; Rajurkar M; Cotton JL; Fan Q; Lewis BC; Ji H; Mao J
Mol Cell; 2013 Jul; 51(2):211-25. PubMed ID: 23769673
[TBL] [Abstract][Full Text] [Related]
10. Tribbles breaking bad: TRIB2 suppresses FOXO and acts as an oncogenic protein in melanoma.
Link W
Biochem Soc Trans; 2015 Oct; 43(5):1085-8. PubMed ID: 26517928
[TBL] [Abstract][Full Text] [Related]
11. Tribbles in disease: Signaling pathways important for cellular function and neoplastic transformation.
Yokoyama T; Nakamura T
Cancer Sci; 2011 Jun; 102(6):1115-22. PubMed ID: 21338441
[TBL] [Abstract][Full Text] [Related]
12. Tribbles 2 (Trib2) is a novel regulator of toll-like receptor 5 signaling.
Wei SC; Rosenberg IM; Cao Z; Huett AS; Xavier RJ; Podolsky DK
Inflamm Bowel Dis; 2012 May; 18(5):877-88. PubMed ID: 22271508
[TBL] [Abstract][Full Text] [Related]
13. TRIB2 inhibits Wnt/β-Catenin/TCF4 signaling through its associated ubiquitin E3 ligases, β-TrCP, COP1 and Smurf1, in liver cancer cells.
Xu S; Tong M; Huang J; Zhang Y; Qiao Y; Weng W; Liu W; Wang J; Sun F
FEBS Lett; 2014 Nov; 588(23):4334-41. PubMed ID: 25311538
[TBL] [Abstract][Full Text] [Related]
14. Overexpression of TRIB2 in human lung cancers contributes to tumorigenesis through downregulation of C/EBPα.
Grandinetti KB; Stevens TA; Ha S; Salamone RJ; Walker JR; Zhang J; Agarwalla S; Tenen DG; Peters EC; Reddy VA
Oncogene; 2011 Jul; 30(30):3328-35. PubMed ID: 21399661
[TBL] [Abstract][Full Text] [Related]
15. Impaired phosphorylation and ubiquitination by p70 S6 kinase (p70S6K) and Smad ubiquitination regulatory factor 1 (Smurf1) promote tribbles homolog 2 (TRIB2) stability and carcinogenic property in liver cancer.
Wang J; Zhang Y; Weng W; Qiao Y; Ma L; Xiao W; Yu Y; Pan Q; Sun F
J Biol Chem; 2013 Nov; 288(47):33667-33681. PubMed ID: 24089522
[TBL] [Abstract][Full Text] [Related]
16. TRIB2 and the ubiquitin proteasome system in cancer.
Salomè M; Campos J; Keeshan K
Biochem Soc Trans; 2015 Oct; 43(5):1089-94. PubMed ID: 26517929
[TBL] [Abstract][Full Text] [Related]
17. Tribbles homolog 2 (Trib2) and HoxA9 cooperate to accelerate acute myelogenous leukemia.
Keeshan K; Shestova O; Ussin L; Pear WS
Blood Cells Mol Dis; 2008; 40(1):119-21. PubMed ID: 17988908
[TBL] [Abstract][Full Text] [Related]
18. Molecular dynamics and structural analysis of the binding of COP1 E3 ubiquitin ligase to β-catenin and TRIB pseudokinases.
Zahid S; Basharat S; Fakhar M; Rashid S
Proteins; 2022 Apr; 90(4):993-1004. PubMed ID: 34881468
[TBL] [Abstract][Full Text] [Related]
19. Covalent inhibitors of EGFR family protein kinases induce degradation of human Tribbles 2 (TRIB2) pseudokinase in cancer cells.
Foulkes DM; Byrne DP; Yeung W; Shrestha S; Bailey FP; Ferries S; Eyers CE; Keeshan K; Wells C; Drewry DH; Zuercher WJ; Kannan N; Eyers PA
Sci Signal; 2018 Sep; 11(549):. PubMed ID: 30254057
[TBL] [Abstract][Full Text] [Related]
20. The presence of C/EBPα and its degradation are both required for TRIB2-mediated leukaemia.
O'Connor C; Lohan F; Campos J; Ohlsson E; Salomè M; Forde C; Artschwager R; Liskamp RM; Cahill MR; Kiely PA; Porse B; Keeshan K
Oncogene; 2016 Oct; 35(40):5272-5281. PubMed ID: 26996668
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
